Ampio Pharmaceuticals (AMPE) 10-K27 Mar 242023 FY Annual reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2023	Mar. 15, 2024	Jun. 30, 2023
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-35182
Entity Registrant Name	AMPIO PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-0179592
Entity Address, Address Line One	9800 Mount Pyramid Court
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	437-6500
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AMPE
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 3.4
Entity Common Stock, Shares Outstanding		1,135,358
Auditor Name	Moss Adams LLP
Auditor Location	Denver, Colorado
Auditor Firm ID	659
Entity Central Index Key	0001411906
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2023		Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 4,089,000		$ 12,653,000
Insurance recovery receivable	920,000		0
Prepaid expenses and other	727,000		676,000
Total current assets	5,736,000		13,329,000
Fixed assets, net	0		184,000
Right-of-use asset, net	0		75,000
Total assets	5,736,000		13,588,000
Current liabilities
Accounts payable and accrued expenses	2,102,000		852,000
Lease liability-current portion	274,000		340,000
Total current liabilities	2,376,000		1,192,000
Lease liability-long-term	0		274,000
Warrant derivative liability	0		44,000
Asset retirement obligation	0		289,000
Total liabilities	2,376,000		1,799,000
Commitments and contingencies (Note 6)
Stockholders' equity
Common Stock, par value $0.0001; 300,000,000 shares authorized; shares issued and outstanding - 833,430 as of December 31, 2023 and 804,674 as of December 31, 2022	0	[1]	0
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; shares issued and outstanding - none as of December 31, 2023 and December 31, 2022
Additional paid-in capital	245,887,000		245,728,000
Accumulated deficit	(242,527,000)		(233,939,000)
Total stockholders' equity	3,360,000		11,789,000
Total liabilities and stockholders' equity	$ 5,736,000		$ 13,588,000

[1] December 31, 2023 balances have been adjusted and December 31, 2022 balances have been retroactively adjusted to reflect the 20 -to-1 reverse stock split effected September 12, 2023.

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical)	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares
Balance Sheets
Common Stock, par value \| $ / shares	$ 0.0001	$ 0.0001
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	833,430	804,674
Common Stock, shares outstanding	833,430	804,674
Preferred stock, par value \| $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Stock split ratio	20

Statements of Operations

Statements of Operations - USD ($)		12 Months Ended
Statements of Operations - USD ($)		Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development		$ 2,439,000	$ 8,916,000
General and administrative		7,079,000	11,466,000
Long-lived assets impairment		0	1,614,000
Right of use asset impairment		0	322,000
Loss on sale of fixed assets		56,000	0
Total operating expenses		9,574,000	22,318,000
Other income
Interest income		348,000	220,000
Rental income		305,000
Gain from elimination of ARO obligation, net		289,000
Derivative gain		0	5,761,000
Total other income		942,000	5,981,000
Net loss		$ (8,632,000)	$ (16,337,000)
Net loss per common share:
Basic (in dollars per share)	[1]	$ (10.66)	$ (21.68)
Diluted (in dollars per share)	[1]	$ (10.66)	$ (29.32)
Weighted average number of common shares outstanding:
Basic (in shares)	[1]	810,113	753,615
Diluted (in shares)	[1]	810,113	753,615

[1]Net loss per common share and weighted average number of common shares outstanding for the current period have been adjusted and the prior periods have been retroactively adjusted to reflect the 20-to-1 reverse stock split effected September 12, 2023.

Statements of Operations (Paren

Statements of Operations (Parenthetical)	Dec. 31, 2023	Sep. 12, 2023	Sep. 11, 2023	Nov. 09, 2022
Statements of Operations
Stock split ratio	20	20	20	15

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Preferred Stock Series D Preferred	Common Stock Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-in Capital	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Deficit	Cumulative Effect, Period of Adoption, Adjustment	Total
Beginning Balance at Dec. 31, 2021			$ 0		$ 244,886,000		$ (217,602,000)		$ 27,284,000
Beginning Balance, Shares at Dec. 31, 2021			808,136
Share-based compensation, net of forfeitures			$ 0		1,462,000		0		1,462,000
Shares held back in settlement of tax obligation for shares issued in connection with restricted stock awards			$ 0		(79,000)		0		(79,000)
Shares held back in settlement of tax obligation for shares issued in connection with restricted stock awards (Shares)			(462)
Offering costs related to the issuance of common stock and warrants in connection with the registered direct offering			$ 0		(32,000)		0		(32,000)
Restricted stock award forfeitures			$ 0		(509,000)		0		(509,000)
Restricted stock award forfeitures (Shares)			(3,000)
Net loss			$ 0		0		(16,337,000)		(16,337,000)
Ending Balance at Dec. 31, 2022			$ 0		245,728,000		(233,939,000)		11,789,000
Ending Balance, Shares at Dec. 31, 2022			804,674
Share-based compensation, net of forfeitures			$ 0		159,000		0		159,000
Shares held back in settlement of tax obligation for shares issued in connection with restricted stock awards			$ 0		0		0		0
Shares held back in settlement of tax obligation for shares issued in connection with restricted stock awards (Shares)			(70)
Common stock issued related to the ATM Equity Offering Program			$ 0		98,000		0		98,000
Common stock issued related to the ATM Equity Offering Program (Shares)			28,826
Offering costs for the common stock issued related to the ATM Equity Offering Program			$ 0		(98,000)		0		(98,000)
Net loss			0		0		(8,632,000)		(8,632,000)
Ending Balance at Dec. 31, 2023		$ 0	$ 0	$ 0	$ 245,887,000	$ 44,000	$ (242,527,000)	$ 44,000	$ 3,360,000
Ending Balance, Shares at Dec. 31, 2023			833,430
Changes in Mezzanine Equity
Issuance of Series D preferred stock dividend	15,103		0		0		0		0
Preferred stock redemption (in shares)	(15,103)		0		0		0		0

Condensed Statements of Mezzani

Condensed Statements of Mezzanine Equity and Stockholders' Equity (Parenthetical)	Dec. 31, 2023	Sep. 12, 2023	Sep. 11, 2023	Nov. 09, 2022
Statements of Stockholders' Equity
Stock split ratio	20	20	20	15

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Cash flows used in operating activities
Net loss	$ (8,632,000)	$ (16,337,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation, net of forfeitures	159,000	1,462,000
Restricted stock award compensation, forfeitures	0	(509,000)
Depreciation and amortization	122,000	1,048,000
Long-lived assets impairment	0	1,614,000
Right-of-use asset impairment	0	322,000
Loss on sale of fixed assets	56,000	0
Net gain from elimination of ARO obligation	(289,000)	7,000
Accretion of asset retirement obligation	5,000
Derivative gain	0	(5,761,000)
Changes in operating assets and liabilities:
Increase in insurance recovery receivable	(920,000)	0
(Increase) decrease in prepaid expenses and other	(51,000)	1,064,000
Increase (decrease) in accounts payable and accrued expenses	1,251,000	(3,959,000)
Decrease in lease liability	(265,000)	(79,000)
Net cash used in operating activities	(8,564,000)	(21,128,000)
Cash flows used in investing activities
Net cash used in investing activities	0	0
Cash flows used in financing activities
Proceeds from sale of common stock in connection with the "at-the-market" equity offering program	98,000	0
Costs related to sale of common stock in connection with the "at-the-market" equity offering program	(98,000)	0
Costs related to the sale of common stock and warrants in connection with the registered direct offering	0	(32,000)
Funding of tax obligation relative to shares withheld in connection with restricted stock awards	0	(79,000)
Net cash used in financing activities	0	(111,000)
Net change in cash and cash equivalents	(8,564,000)	(21,239,000)
Cash and cash equivalents at beginning of period	12,653,000	33,892,000
Cash and cash equivalents at end of period	4,089,000	12,653,000
Non-cash transactions:
Commercial insurance premium financing agreement	703,000	1,159,000
Recognition of asset retirement obligation	$ 0	$ 282,000

Basis of Presentation

Basis of Presentation	12 Months Ended
Basis of Presentation	Dec. 31, 2023
Basis of Presentation
Basis of Presentation	Note 1 – Basis of Presentation The accompanying financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”). Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) is a pre-revenue stage biopharmaceutical company, located in Englewood, CO, that was focused solely on the development of a potential treatment for Osteoarthritis of the Knee (“OAK”) as part of the OA-201 program. The OA-201 program sought to advance Ampio’s unique and proprietary small molecule formulation that was Ampio’s only product development opportunity. The Company’s core activities in 2023 relate to research and development and raising capital. The Company has not generated operating revenue to date. In late 2023, we initiated non-clinical studies to determine whether OA-201 would support an Investigational New Drug (“IND”) submission. Previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce pain and preserve cartilage in non-clinical models of osteoarthritis of the knee. However, as we announced in February 2024, the pain reduction benefit was not observed in the data from the recent set of non-clinical studies which utilized a larger population of animal subjects. Because the data from the larger non-clinical pain reduction trial of OA-201 did not support the same pain reduction benefit as was demonstrated in the earlier trials, Ampio determined to cease all preclinical and clinical development activities relating to OA-201. On November 9, 2022, the Company effected a 15-to-1 reverse stock split. On September 12, 2023, the Company effected a 20-to-1 reverse stock split. The Company has applied and retroactively applied, the reverse stock splits to share and per share amounts in the financial statements as of December 31, 2023 and December 31, 2022, respectively. Additionally, pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all the Company’s outstanding options under the 2010/2019 Stock and Incentive Plans, the number of shares of restricted stock outstanding under the 2019 Stock and Incentive Plan, and common stock warrants, with any fractional shares rounded up to the next whole share. The number of shares authorized for issuance pursuant to the Company’s 2023 Stock and Incentive Plan (the “2023 Plan”) was not impacted by the 20-to-1 reverse stock split (see Note 9

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2023
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions primarily include the Company’s projected current and long-term liquidity needs and availability and the insurance recovery receivable. The Company develops these estimates using its judgment based upon experience and the facts and circumstances known at the time. Cash and Cash Equivalents The Company considers instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s investment policy is to preserve principal and maintain liquidity. On March 10, 2023, the Federal Deposit Insurance Corporation (“FDIC”) placed Silicon Valley Bank (“SVB”) into receivership. At that time, the Company held approximately in a deposit account at SVB. The balance of the Company’s cash was held in an investment account that was not a deposit account and therefore, these amounts were not impacted by the FDIC’s receivership of SVB or subject to FDIC insurance limits. Following the joint statement by the U.S. Treasury, Federal Reserve and the FDIC on March 12, 2023, the Company regained access to all of its deposit account funds. The Company refined its cash management strategy in order to further mitigate the potential risk of loss associated with deposit accounts balances in excess of the FDIC insured amount. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the year ended December 31, 2023, the Company did not maintain balances in excess of the federally insured limits; however, during the year ended December 31, 2022, the Company maintained balances in excess of federally insured limits. Insurance Recovery Receivable During the second quarter of 2023, the Company’s legal expenses associated with the litigation proceedings exceeded the retention limit per the insurance policy and, as such, legal expenses incurred subsequently are covered and reimbursed by the insurance carrier. As of December 31, 2023, the Company estimated an insurance recovery receivable of Fixed Assets Effective March 1, 2023, the Company entered into a sublease of its existing facility and in connection with that sublease, entered into a bill of sale with the subtenant for all the Company’s existing fixed assets (see Note 4 Impairment of Long-Lived Assets The Company performs an evaluation on an annual basis, or sooner if management believes a triggering event has occurred, of the recoverability related to the carrying value of its long-lived assets to determine if facts and circumstances indicate that the carrying value of assets may be impaired and if any adjustment is warranted. As noted above, there were no long-lived or ROU assets to evaluate as of December 31, 2023. However, the Company recorded impairment charges of $1.6 million and $0.3 million on its long-lived and ROU assets, respectively, during the year ended December 31, 2022. Fair Value of Financial Instruments The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. The carrying amounts of cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short maturity of these instruments. In prior years, the Company recorded a warrant derivative liability associated with former offerings at estimated fair value based on utilization of the Black-Scholes warrant pricing model depending on facts and circumstances. However, the Company early adopted ASU 2020-06, resulting in the reclassification of the warrant derivative liability to stockholders’ equity, effective January 1, 2023. See Note 7 and Note 8 Share-Based Compensation The Company accounts for share-based payments by recognizing compensation expense based upon the estimated fair value of the share-based payments on the date of grant. The Company determines the estimated fair value of the share-based payments granted using the fair market value or Black-Scholes option pricing model and recognizes compensation costs ratably over the requisite service period which approximates the vesting period using the graded method. See Note 10 Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its net deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through projected future taxable income, based primarily on the Company’s ongoing history of operating losses and the lack of taxable income in the foreseeable future. See Note 11 Research and Development Research and development costs are expensed as incurred in the respective periods. Liquidity The Company is a pre-revenue stage biopharmaceutical company that has incurred an accumulated deficit of $242.5 million as of December 31, 2023. As of December 31, 2023, the Company had $4.1 million of cash and cash equivalents and an insurance recovery receivable of $0.9 million. As of February 29, 2024, the Company had $3.4 million in cash and cash equivalents and $0.5 million of an insurance recovery receivable. While the Company continued to implement cost reductions in 2023 and additional cost reductions in February and March 2024, the Company has finite cash resources available to fund its now limited operations. Its activities currently consist of taking steps to preserve cash to adequately fund an orderly wind down of the Company’s operations and to maximize the Company’s cash position and pursuit of the resolution of currently pending legal proceedings. Consistent with this goal, on March 25, 2024, the Board of Directors determined to pursue voluntary delisting of Ampio’s common stock from the NYSE American. After delisting, the Company expects to suspend its reporting obligations under the Exchange Act and deregister its common stock under Section 12(b) of the Exchange Act. Based on the above, these conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities; however, such adjustments may be necessary in the future when the Company is unable to continue as a going concern. Adoption of Recent Accounting Pronouncements In August 2020, the Financial Accounting Standard Board (the “FASB”) issued ASU 2020-06, “ Debt (Subtopic 470-20); Debt with Conversion and Other Options and Derivatives and Hedging (Subtopic 815-40) Contracts in Entity’s Own Equity Recent Accounting Pronouncements This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Prepaid Expenses and Other

Prepaid Expenses and Other	12 Months Ended
Prepaid Expenses and Other	Dec. 31, 2023
Prepaid Expenses and Other
Prepaid Expenses and Other	Note 3 – Prepaid Expenses and Other Prepaid expenses and other balances as of December 31, 2023 and 2022 are as follows: December 31, 2023 December 31, 2022 Unamortized commercial insurance premiums $ 339,000 $ 610,000 Non-clinical trials (upfront payments) 215,000 — Deferred issuance costs 136,000 — Deposits 34,000 34,000 Other 3,000 32,000 Total prepaid expenses and other $ 727,000 $ 676,000

Fixed Assets

Fixed Assets	12 Months Ended
Fixed Assets	Dec. 31, 2023
Fixed Assets
Fixed Assets	Note 4 – Fixed Assets Fixed assets balances, net of accumulated depreciation, as of December 31, 2023 and 2022 are as follows: Estimated Useful Lives (in Years) December 31, 2023 December 31, 2022 Leasehold improvements 10 $ — $ 4,965,000 Manufacturing facility/clean room 3 - 8 — 2,803,000 Lab equipment and office furniture 5 - 8 — 1,661,000 Fixed assets, gross — 9,429,000 Accumulated depreciation — (9,245,000) Fixed assets, net $ — $ 184,000 In accordance with ASC Topic 360, Property, Plant and Equipment, the Company assesses all of its long-lived assets for impairment when impairment indicators are identified. During the third quarter of 2022, the Company announced that it was discontinuing further development of its lead pipeline, Ampion. This announcement was identified as an impairment indicator and, as such, the Company recorded a non-cash impairment as of September 30, 2022 related to its long-lived assets. The Company utilized a market valuation approach for determining the fair value of the ROU asset and a combination of the indirect cost approach and market approach for determining the fair value of the long-lived fixed assets. Based on this analysis, the Company concluded that the carrying value of the assets exceeded its undiscounted cash flows, and, as such, an impairment loss, calculated as the difference between carrying value and fair value, was deemed necessary. Accordingly, the Company recorded a $1.6 million impairment loss during the third quarter of 2022 as a direct reduction to the cost basis of the affected assets. Due to the impairment in the prior year, there were no fixed assets to evaluate or impair as of December 31, 2023. Depreciation expense as of December 31, 2023 and 2022 is as follows: Year Ended December 31, 2023 2022 Depreciation and amortization expense $ 122,000 $ 1,048,000

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
Accounts Payable and Accrued Expenses	Dec. 31, 2023
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	Note 5 – Accounts Payable and Accrued Expenses Accounts payable and accrued expenses as of December 31, 2023 and 2022 is as follows: December 31, 2023 December 31, 2022 Accounts payable $ 750,000 $ 97,000 Professional fees 706,000 157,000 Manufacturing development 274,000 — Commercial insurance premium financing 177,000 189,000 Non-clinical and clinical trials 73,000 89,000 Subtenant security deposit 62,000 — Franchise taxes 22,000 78,000 Property taxes — 74,000 Accrued severance — 143,000 Other 38,000 25,000 Accounts payable and accrued expenses $ 2,102,000 $ 852,000 Commercial Insurance Premium Financing In June 2023, the Company entered into an insurance premium financing agreement for $0.7 million, with a term of nine months and an annual interest rate of 8.00% and made a down payment of $171,000 . Under the terms and provisions of the agreement, the Company is required to make principal and interest payments totaling $59,000 per month over the remaining term of the agreement. The outstanding obligation of $177,000 as of December 31, 2023 was paid in full in March 2024.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2023
Commitments and Contingencies
Commitments and Contingencies	Note 6 – Commitments and Contingencies Employment Agreements As of December 31, 2023, the Company is a party to an employment agreement with Michael A. Martino, Chief Executive Officer, dated November 22, 2021 and amended August 30, 2022 with an initial base salary of $550,000. The amendment on August 30, 2022 extended the term to November 22, 2023. On October 1, 2023, the Company and Michael A. Martino entered into a second amendment to the employment agreement, which changed the term ending on November 22, 2023 to an indefinite term. All other terms and conditions of Mr. Martino’s employment agreement remain unchanged. As of December 31, 2023, the Company is a party to an employment agreement dated October 11, 2021 with Daniel Stokely to serve in the capacity as the Company’s Chief Financial Officer with an initial base salary of $335,000 and an initial term ending in October 2024. Under these employment agreements, each executive is entitled to a severance payment in the event the Company terminates employee’s employment without cause, or employee terminates his employment with good reason. On March 25, 2024, the Board of Directors determined to terminate the employment of Mr. Stokely effective March 31, 2024 in order to preserve cash to adequately fund an orderly wind down of the Company’s operations and to maximize the Company’s cash position. Pursuant to his employment agreement, Mr. Stokely will be entitled to severance and COBRA reimbursement, conditioned on, among other things, Mr. Stokely delivering and not revoking a general release of claims against the Company. Manufacturing Development In September 2023, the Company entered into a manufacturing development agreement with a contract development and manufacturing organization (“CDMO”), which reflected an initial scope of work for the OA-201 program totaling $1.6 million. The initial scope of work included analytical method development, formulation development, and GLP animal study supply on the prototype formulations of OA-201. In addition, the CDMO will prepare GMP supply of the formulation and complete a corresponding stability study. In December 2023, the Company executed a change order with the CDMO for an additional $20,000. In February 2024, the Company terminated the manufacturing development agreement with the CDMO. As of March 15, 2024, the Company has an obligation for accrued and unpaid services and related expenses of $160,000. Non-Clinical Trials In September 2023, the Company entered into a non-clinical trial agreement with a research institute to conduct an animal study totaling $105,000. In December 2023, the Company executed a change order with the research institute for an additional $117,000 . Payments are based on the completion of milestones, with the first payment due upon execution of the agreement. However, the Company systematically amortizes or accrues expenses when incurred. In February 2024, the Company terminated the non-clinical trial agreement with the research institute. As of March 15, 2024, the Company has an obligation for accrued and unpaid services and related expenses of In December 2023, the Company entered into four additional non-clinical trial agreements with another research institute to conduct a series of animal studies totaling $625,000. Payments are based on the completion of milestones, with the first payments due upon execution of the agreements. However, the Company systematically amortizes or accrues expenses when incurred. In February 2024, the Company terminated the non-clinical trial agreements with the research institute. As of March 15, 2024, the Company had no obligation for accrued and unpaid services and related expenses. Facility Lease The Company is a party to a Lease Agreement (the “Lease”) with Beta Investors Group, LLC (successor by assignment to NCWP – Inverness Business Park, LLC) (the “Landlord”) dated December 13, 2013 pursuant to which the Company has leased office and manufacturing space in Suite 200 and Suite 204 in the building located at 373 Inverness Parkway, Englewood, Colorado (the “Premises”). The lease is a 125-month Effective March 1, 2023, the Company entered into a sublease agreement whereby the Company subleased the Premises for a term commencing on March 1, 2023 and continuing until the expiration for the Lease on September 30, 2024. The subtenant will pay to the Company rent and other amounts assessed by the Landlord against the Company under the Lease. The subtenant is also fully responsible for utilities and insurance under the sublease agreement. Under the terms and conditions of the sublease agreement, the Company was fully released of its obligation under the Lease to dismantle and remove certain components of leasehold improvements at the end of the lease term. Accordingly, the Company derecognized its asset retirement obligation (“ARO”) in the amount of $294,000 which resulted in the recognition of a non-cash gain totaling $289,000 gain, net of $5,000 loss on the derecognition of the ARO asset. The following table provides a reconciliation of the Company’s remaining undiscounted payments for its facility lease and the carrying amount of the lease liability presented in the balance sheet as of December 31, 2023: Facility Lease Payments 2024 2025 2026 2027 2028 Thereafter Remaining Facility Lease Payments $ 280,000 $ 280,000 $ $ — $ — $ — $ — Less: Discount Adjustment (6,000) Total lease liability $ 274,000 Lease liability-current portion $ 274,000 Long-term lease liability $ — The Company recorded lease expense in the respective periods is as follows: Year Ended December 31, 2023 2022 Lease expense $ 113,000 $ 221,000

Warrants

Warrants	12 Months Ended
Warrants	Dec. 31, 2023
Warrants.
Warrants	Note 7 – Warrants As disclosed in Note 2 Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding as of December 31, 2022 53,263 $ 318.80 3.80 Forfeited, expired and/or cancelled (17,179) Outstanding as of December 31, 2023 36,084 $ 316.28 2.77 The following table summarizes the Company’s outstanding warrants between placement agent and investor warrant classifications: Weighted Weighted Average Number of Average Remaining Date Exercise Price Type Warrants Exercise Price Contractual Life December 2021 registered direct offering $ 330.00 Investor 33,334 2.73 June 2019 public offering $ 150.00 Placement agent 2,750 0.04 Outstanding as of December 31, 2023 36,084 $ 316.28 2.77 In August 2023, a total of 512 investor warrants expired. A total of 16,667 of the 2021 Warrants were abandoned in December 2023. Pursuant to a waiver letter dated December 18, 2023, the warrant holders irrevocably abandoned all of their rights, title, and interest to the 2021 Warrants and any common stock underlying the 2021 Warrants for no consideration. There were no issuances or exercises of warrants during the year ended December 31, 2023. Due to the adoption of ASU 2020-06, there was also no warrant derivative liability as of December 31, 2023. The total value for the warrant derivative liability as of December 31, 2022 was approximately $44,000 (see Note 8

Fair Value Considerations

Fair Value Considerations	12 Months Ended
Fair Value Considerations	Dec. 31, 2023
Fair Value Considerations
Fair Value Considerations	Note 8 – Fair Value Considerations Authoritative guidance defines fair value as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources not affiliated with the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to the Company for identical assets or liabilities; Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. Warrants are recorded at estimated fair value utilizing the Black-Scholes warrant pricing model. The Company’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company’s policy is to recognize transfers in and/or out of the fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. The Company has consistently applied the valuation techniques in all periods presented. The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2023 and 2022, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total December 31, 2023 Liabilities: Warrant derivative liability $ — $ — $ — $ — December 31, 2022 Liabilities: Warrant derivative liability $ — $ — $ 44,000 $ 44,000 Due to the implementation of ASU 2020-06, effective January 1, 2023 the fair value of financial liabilities classified as Level 3 in the fair value hierarchy was reduced by $44,000. There were no financial liabilities classified as Level 1, 2 or 3 as of December 31, 2023 The warrant derivative liability for the December 31, 2022 period presented was valued using the Black-Scholes valuation methodology as the Company believes that model embodies all the relevant assumptions (including trading volatility, estimated terms and risk-free interest rates) that address the features underlying these instruments.

Common Stock

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2023
Common Stock.
Common stock	N Authorized Shares The Company had 300.0 million authorized shares of common stock as of December 31, 2023 and 2022. The following table summarizes the Company’s remaining authorized shares available for future issuance: December 31, 2023 Authorized shares 300,000,000 Common stock outstanding 833,430 Options outstanding 12,291 Warrants outstanding 36,084 Reserved for issuance under 2019 Stock and Incentive Plan — Reserved for issuance under 2023 Stock and Incentive Plan 1,200,000 Available shares for future issuance 297,918,195 ATM Equity Offering Program On September 18, 2023, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC as Manager (in such capacity, the “Manager”), establishing an at-the-market equity distribution program, pursuant to which the Company, through the Manager, may offer and sell from time to time shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), having an aggregate gross sales price of up to $1,250,000 . The Registration Statement on Form S-3 (File No. 333-274558) (the “Registration Statement”) which included a base prospectus and an at-the-market offering prospectus was filed by the Company on September 18, 2023 and became effective on September 27, 2023. Subject to the terms and conditions of the ATM Agreement, the Manager may sell Common Stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The Manager will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the Manager a commission of 3.0% of the gross sales proceeds of each sale of shares pursuant to the ATM Agreement. The Company will also reimburse the Manager for the documented fees and costs of its legal counsel reasonably incurred in connection with entering into the transactions contemplated by the ATM Agreement in an amount not to exceed $50,000 in the aggregate, as well as an additional reimbursement of up to $2,500 per due diligence update session for the Manager’s fees. The Company has provided customary representations, warranties and covenants, and the parties have agreed to customary indemnification rights. The Company has the right to terminate the provisions of the ATM Agreement in its sole discretion at any time upon seven business days’ prior written notice. The Manager has the right to terminate the ATM Agreement in its sole discretion at any time. In the case of a termination by either party, specified provisions of the ATM Agreement will survive, including the indemnification provisions. Under the terms of the ATM Agreement, in no event will the Company issue or sell through the Manager such number or dollar amount of shares of Common Stock that would (i) exceed the number or dollar amount of shares of Common Stock registered and available on the Registration Statement, (ii) exceed the number of authorized but unissued shares of Common Stock, or (iii) exceed the number or dollar amount of Common Stock for which the Company has filed a prospectus supplement to the Registration Statement. As of December 31, 2023, the Company sold 28,826 shares of common stock under the ATM Agreement, generating gross proceeds of $0.1 million, which was offset by placement agent commissions and issuance costs of $0.1 million. On February 26, 2024, the Company terminated the ATM Agreement with the Manager effective as of March 6, 2024. On February 28, 2024, the Company filed a post-effective amendment to deregister the remaining securities available under the Registration Statement relating to the offerings under the ATM Agreement, which was declared effective by the SEC on March 4, 2024.

Mezzanine Equity and Stockholde

Mezzanine Equity and Stockholders' Equity	12 Months Ended
Mezzanine Equity and Stockholders' Equity	Dec. 31, 2023
Mezzanine Equity and Stockholders' Equity
Mezzanine Equity and Stockholders' Equity	Note 10 – Mezzanine Equity and Stockholders’ Equity Preferred Stock On May 24, 2023, the Board declared a dividend of one one-thousandth of a share (1/1000 th Series D Preferred Stock Common Stock Record Date Each share of Series D Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each ten whole shares of Series D Preferred Stock that are beneficially owned by the beneficial owner. From July 27, 2023 to the date hereof, there have been no Redemption Payment Requests. The shares of Series D Preferred Stock were classified within the mezzanine equity in the Company’s condensed consolidated balance sheet as of June 30, 2023. The shares of Series D Preferred Stock were measured at redemption value which was considered immaterial to the Company’s financial statements at the time of issuance. As of December 31, 2023, all shares of Series D Preferred Stock have been cancelled and returned to the status of authorized but unissued shares of preferred stock. Options In July 2023, the Company’s Board of Directors and stockholders approved the adoption of the 2023 Plan, under which shares were reserved for future issuance of equity related awards as further defined under the 2023 Plan. The 2023 Plan permits grants of equity awards to employees, directors and consultants. The stockholders approved a total of 1.2 million shares to be reserved for issuances under the 2023 Plan and the full amount of the reserve remains available for future issuances as of December 31, 2023. Pursuant to the terms of the 2023 Plan, the number of shares authorized for issuance pursuant to the 2023 Plan were not impacted by the 20-to-1 reverse stock split. The Company has no authority to grant new awards from the 2010 Stock and Incentive Plan or the 2019 Stock and Incentive Plan (collectively, the “Prior Plans”). However, approval of the 2023 Plan does not affect awards outstanding under the Prior Plans, which will continue in accordance with their terms. The following table summarizes the Company’s stock option activity at December 31, 2023: Weighted Weighted Average Number of Average Remaining Aggregate Options Exercise Price Contractual Life Intrinsic Value Outstanding as of December 31, 2022 14,873 $ 299.40 6.41 $ — Granted — Exercised — Forfeited, expired and/or cancelled (2,582) $ 352.49 Outstanding as of December 31, 2023 12,291 $ 288.12 6.81 $ — Exercisable as of December 31, 2023 11,652 $ 288.14 6.74 $ — Outstanding options that were issued in accordance with the 2010 Plan and 2019 Plan are summarized in the table below: Outstanding Options by Plan December 31, 2023 2010 Plan 4,508 2019 Plan 7,783 Outstanding as of December 31, 2023 12,291 Stock options outstanding at December 31, 2023 are summarized in the table below: Number of Weighted Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Lives Up to $150.00 2,040 $ 132.37 6.80 $150.01 - $300.00 5,935 $ 206.45 6.30 $300.01 - $450.00 2,620 $ 346.95 7.86 $450.01 and above 1,696 $ 670.16 6.98 Total 12,291 $ 288.12 6.81 Restricted Stock Awards The restricted stock awards activity for the period ending December 31, 2023 is summarized in the table below: Weighted Average Grant-Date Aggregate Awards Fair Value Intrinsic Value Nonvested as of December 31, 2022 670 $ 492.00 Vested (223) $ 492.00 $ — Forfeited — Nonvested as of December 31, 2023 447 $ 492.00 The unvested restricted stock awards at December 31, 2023 will vest equally on January 1, 2024 and 2025, respectively. Share-based Compensation The Company computes the fair value for all options granted or modified using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company calculates its volatility assumption using the actual changes in the market value of its stock. Forfeitures are recognized as they occur. The Company’s historical option exercises do not provide a reasonable basis to estimate an expected term due to the lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method. The simplified method calculates the expected term as the average of the vesting term plus the contractual life of the options. The risk- free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The Company did not grant or modify options during the period ending December 31, 2023, as such, there are no assumptions to compute the fair value of options. The Company computed the fair value of options granted and modified during the period ended December 31, 2022 using the following assumptions: Year Ended December 31, 2022 Expected volatility 116.83% - 119.43 % Risk free interest rate 1.26% - 1.94 % Expected term (years) 5.45 - 6.51 The Company also computes the fair value for all restricted stock awards based on the closing stock price on the grant date and recognizes share-based compensation ratably over the requisite service period which approximates the vesting period. The Company recognized $83,000 of share-based compensation related to restricted stock awards as of December 31, 2023. The Company recognized $0.5 million of share-based compensation relating to restricted stock awards which was fully offset by $0.5 million due to forfeitures as of December 31, 2022. Share-based compensation expense related to the fair value of stock options and restricted stock awards is included in the statements of operations as research and development expenses and general and administrative expenses as set forth in the table below. The Company determined the fair value as of the date of grant for options using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation for the years ended December 31, 2023 and December 31, 2022: Year Ended December 31, 2023 2022 Research and development expenses Share-based compensation, net of forfeitures $ (25,000) $ 139,000 General and administrative expenses Share-based compensation, net of forfeitures 184,000 814,000 Total share-based compensation, net of forfeitures $ 159,000 $ 953,000 Unrecognized share-based compensation expense related to stock options as of December 31, 2023 $ 28,000 Weighted average remaining years to vest for stock options 1.00 Unrecognized share-based compensation expense related to restricted stock awards as of December 31, 2023 $ 34,000 Weighted average remaining years to vest for restricted stock awards 1.01

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2023
Income Taxes
Income Taxes	Note 11 – Income Taxes Income tax expense (benefit) resulting from applying statutory rates in jurisdictions in which the Company is taxed (Federal and State of Colorado) differs from the income tax provision (benefit) in the Company’s financial statements. The following table reflects the reconciliation for the respective periods: Year Ended December 31, 2023 2022 Benefit at federal statutory rate (21.0) % (21.0) % State, net of federal income tax impact (3.4) % (4.0) % Stock-based compensation 0.8 % 4.0 % Registered offering loss (gain)/warrant expense 0.0 % (7.2) % Change in state deferred tax rate 0.0 % 1.5 % Expiration of tax attribute carryforwards 0.3 % 0.6 % Other 0.0 % 0.0 % Change in valuation allowance 23.3 % 26.1 % Effective tax rate 0.0 % 0.0 % Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: Year Ended December 31, 2023 2022 Long-term deferred income tax assets (liabilities): Accrued liabilities $ — $ 3,000 ROU asset — (18,000) Lease liability 67,000 150,000 Net operating loss carryforward 51,902,000 50,196,000 Share-based compensation 424,000 459,000 Unrealized loss on trading security 768,000 768,000 Property and equipment — 606,000 Warrants 65,000 65,000 Capitalized development costs 3,177,000 2,093,000 Asset retirement obligation — 68,000 Other 1,000 1,000 Less: Valuation allowance (56,404,000) (54,391,000) Total long-term deferred income tax assets (liabilities) $ — $ — As of December 31, 2023, Ampio has approximately $212.0 million in net operating loss (“NOL”) carryforwards that, subject to limitation, may be available in future tax years to offset taxable income. These net operating loss carryforwards expire from 2024 through 2037. Approximately $81.5 million of the NOL carryforward carries forward indefinitely. Under the provisions of the Internal Revenue Code, substantial changes in the Company’s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. The Company has provided a full valuation allowance against its deferred tax assets as it has determined that it is not more likely than not that recognition of such deferred tax assets will be utilized in the foreseeable future. The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon recognition of the benefit. The Company believes that it has no material uncertain tax positions and has fully reserved against its future tax benefit with a valuation allowance and does not expect significant changes in the amount of unrecognized tax benefits to occur within the next twelve months. The Company’s policy is to record a liability for the difference between benefits that are both recognized and measured pursuant to GAAP and tax positions taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition. The Company files income tax returns in the United States federal and various state jurisdictions. The Company is no longer subject to income tax examinations for federal income taxes before 2020 or for Colorado before 2019. Net operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOL’s generated as such NOL’s are utilized.

Earnings Per Share

Earnings Per Share	12 Months Ended
Earnings Per Share	Dec. 31, 2023
Earnings Per Share
Earnings Per Share	Note 12 – Earnings Per Share Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is based on the treasury stock method and computed by dividing net loss available to common stockholders by the diluted weighted-average shares of common stock outstanding during each period. The Company’s potentially dilutive shares include stock options, warrants for the shares of common stock and restricted stock awards. The potentially dilutive shares are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when the effect is dilutive. The investor warrants are treated as equity in the calculation of diluted earnings per share in both the computation of the numerator and denominator, if dilutive. The following table sets forth the calculations of basic and diluted earnings per share for the year ended December 31, 2023 and 2022: Year Ended December 31, 2023 2022 Net loss $ (8,632,000) $ (16,337,000) Less: decrease in fair value of investor warrants — (5,761,000) Net loss available to common stockholders $ (8,632,000) $ (22,098,000) Basic weighted-average common shares outstanding 810,113 753,615 Add: dilutive effect of equity instruments — — Diluted weighted-average shares outstanding 810,113 753,615 Earnings per share – basic $ (10.66) $ (21.68) Earnings per share – diluted $ (10.66) $ (29.32) The potentially dilutive shares of common stock equivalents that have been excluded from the calculation of net loss per share because of the anti-dilutive effect as of December 31, 2023 and 2022 are as follows: Year Ended December 31, 2023 2022 Warrants to purchase shares of common stock 36,084 53,257 Outstanding stock options 12,291 14,873 Restricted stock awards 447 670 Total potentially dilutive shares of common stock 48,822 68,800

Litigation

Litigation	12 Months Ended
Litigation	Dec. 31, 2023
Commitments and Contingencies
Litigation	Note 13 – Litigation From time to time, the Company may be a party to litigation arising in the ordinary course of business. In addition, as Kain v. Ampio Pharmaceuticals, Inc., et al., 22-cv-2105 On August 17, 2022, a putative Ampio shareholder filed a securities fraud class action against the Company, its current CEO Michael A. Martino and two former executives, Michael Macaluso and Holli Cherevka, in the United States District Court for the District of Colorado, captioned Kain v. Ampio Pharmaceuticals, Inc., et al. The Complaint relied largely on Ampio’s announcement on May 16, 2022, that it had formed a special Board committee to investigate the statistical analysis of Ampio’s AP-013 clinical trial and the unauthorized provision of Ampion to various individuals who were not participating in clinical trials, and Ampio’s further announcement on August 3, 2022, that the investigation had revealed that various employees were aware that the AP-013 trial did not demonstrate efficacy for Ampion’s primary endpoints and did not fully and timely report the results of the trial and the timing of unblinding data from the trial. Based on the Company’s reports, the Complaint asserted that various statements made by the Company during the Class Period were false and misleading because they: (i) inflated Ampio’s ability to successfully obtain FDA approval for Ampion; (ii) inflated the results of the AP-013 clinical trial and failed to disclose the timing of unblinding the data from the study; and (iii) overstated the Company’s business, operations and prospects. The Complaint sought an unspecified amount of compensatory damages as well as attorneys’ fees and costs. On October 17, 2022, six putative shareholders filed motions seeking to be named lead plaintiff. On November 7, 2022, two of the movants filed oppositions to each other’s motions; the remaining movants either withdrew their motions or filed non-oppositions to another putative shareholder’s motion. On August 9, 2023, the Court ruled on the competing motions for appointment of lead plaintiff, and appointed Tao Wang and SynWorld Technologies Corporation as lead plaintiffs and approved the firm of Faruqi & Faruqi, LLP as lead counsel. The August 9, 2023, order also lifted the stay that had been in place and ordered the parties to jointly contact the magistrate judge to schedule a status conference or such other proceeding as the magistrate judge deemed appropriate to move the litigation forward. Pursuant to the Court’s order, on August 10, 2023, lead plaintiffs and defendants advised the magistrate judge that lead plaintiffs intended to file an amended complaint in the action and that the parties intended to submit a joint proposed scheduling order by August 18, 2023. On August 14, 2023, the Court entered a minute order setting a scheduling conference for August 30, 2023. On August 15, 2023, the parties filed a joint motion with a schedule for lead plaintiffs to file the amended complaint and a deadline for defendants to answer or file motions to dismiss, along with a briefing schedule for any potential motions to dismiss. On August 16, 2023, the Court entered an order granting in part and denying in part the parties’ joint motion. The order vacated the August 30, 2023 scheduling conference and any related deadlines and set lead plaintiffs’ deadline to file an amended complaint as October 16, 2023. It provided that defendants file answers or motions within sixty days of service of the amended complaint. It set a briefing schedule for any potential motions to dismiss. The order further provided that if defendants answer the amended complaint or any motion to dismiss does not fully resolve the case, the parties are required to contact the magistrate judge within 5 business days thereafter to schedule a scheduling conference. On September 19, 2023, defendant Michael Macaluso’s counsel filed a motion to withdraw due to Mr. Macaluso’s death and the lack of a personal representative to represent Mr. Macaluso’s interest. On September 20, 2023, the Court denied the motion without prejudice to refiling and ordered Mr. Macaluso’s counsel to file a Statement Noting the Death pursuant to Rule 25 of the Federal Rules of Civil Procedure and further noting that, if the claims are not extinguished against Mr. Macaluso by his death, any party may file a motion to substitute within 90 days of the filing of the Statement Noting the Death or Mr. Macaluso will be dismissed from the case. On September 20, 2023, Mr. Macaluso’s counsel filed a Suggestion of Death as directed by the Court and renewed his motion to withdraw adding additional information about his efforts to communicate with Mr. Macaluso’s family and the status of any probate proceedings. On September 27, 2023, the Court granted counsel’s renewed motion to withdraw. On October 16, 2023, lead plaintiffs filed an Amended Complaint, asserting the same claims against the Company and adding several additional defendants (namely the Company’s current CFO, Dan Stokely, and former directors David Bar-Or, Philip Coelho and Richard Giles), in addition to the previously named individual defendants Michael Martino, Michael Macaluso and Holli Cherevka. Pursuant to the Court’s order, Defendants had until December 15, 2023 to file answers or motions to dismiss in response to the Amended Complaint. On November 17, 2023, the parties (other than deceased defendant Macaluso) filed a Joint Stipulated Unopposed Motion to Extend Deadlines advising the Court that the parties had agreed to engage in a mediation to be conducted by January 5, 2024, and requesting that the Court vacate the time for all defendants to answer, move or otherwise respond to the Amended Complaint. The motion further requested that the parties be permitted to file a status report advising the Court within five As reported above, at the mediation, the parties reached a settlement in principle, subject to lead plaintiffs completing confirmatory discovery, to the negotiation and execution of final settlement papers, and to the Court approving the settlement. On January 9, 2024, the parties filed a status report with the Court advising it that they had reached agreement in principle and intended to file a motion for court approval within one hundred twenty (120) days. On January 12, 2024, the Court entered a minute order vacating all deadlines and providing, among other things, “The Parties shall submit to the Court a stipulation and agreement of settlement and a motion for preliminary approval of the settlement (including a plan of allocation and procedures for class notice) pursuant to Fed. R. Civ. P. 23(e) on or before May 13, 2024.” The parties are currently engaged in confirmatory discovery and are endeavoring to finalize and file the required settlement documents with the Court by May 14, 2024. Maresca v. Martino, et al., 22-cv-2646-KLM On October 7, 2022, putative Ampio shareholder Robert Maresca filed a Verified Shareholder Derivative Complaint in the United States District Court for the District of Colorado, captioned Maresca v. Martino, et al. Based largely on the same allegations as the Kain The Complaint asserts six causes of action on behalf of the Company and against the individual defendants: (1) violations of Section 14(a) of the Exchange Act based on purportedly false and misleading statements in the Company’s proxy statements; (2) violations of Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder; (3) control person liability under Section 20(a) of the Exchange Act; (4) breach of fiduciary duty; (5) unjust enrichment; and (6) waste of corporate assets. The Complaint seeks an unspecified amount of compensatory and restitution damages to be paid to Ampio, together with pre- and post-judgment interest, as well as injunctive relief imposing certain corporate governance reforms and attorneys’ fees and costs. On November 2, 2022, the Company and plaintiff (together with plaintiff in a second derivative action -- the Marquis On January 10, 2023, after the Company received additional extensions of time to respond, the Court granted consolidation of the Maresca Marquis On January 17, 2023, the parties filed a joint stipulated motion seeking a temporary stay of the consolidated derivative actions, subject to various conditions, until the earlier of: (1) the dismissal of the Kain Kain As reported above, on January 4, 2024, the parties to the Consolidated Derivative Actions participated in a mediation at which they reached agreement in principle. The settlement is subject to various conditions, including the negotiation and execution of the full settlement agreements and obtaining court approval. On January 9, 2024, the parties filed a status report in the Consolidated Derivative Actions, advising the Court of the status of the settlement in principle and that the parties intended to file settlement documents within thirty days. Since then, the parties have filed several further status reports updating the Court on the parties’ continued negotiations and efforts to finalize the settlement documents. Marquis v. Martino, et al., 22-cv-2803-KLM On October 25, 2022, putative shareholder Samantha Marquis filed a derivative complaint in the United States District Court for the District of Colorado, captioned Marquis v. Martino, et al., 22-cv-2803-KLM. The Complaint, filed on behalf of Ampio, asserts that various current and former officers and directors of Ampio – namely, Michael Martino, Michael Macaluso, Holli Cherevka, David Bar-Or, David Stevens, Kevin Buchi, Philip Coelho, and Richard Giles, breached their fiduciary duties as directors and/or officers and violated Section 14(a) of the Exchange Act by causing the Company to file false and misleading proxy statements. The Complaint focuses on the Company’s alleged failure to timely report that the results of the AP-013 trial for Ampion were unfavorable, failing to show efficacy on the co-primary endpoints of pain and function, and the Company’s alleged failure to disclose the results of and timing of unblinding the study data. The Complaint asserts that the individual defendants breached their fiduciary duties by making or causing the Company to make materially false and misleading statements regarding Ampio’s business, operations and prospects and by failing to maintain adequate internal controls. Based on these allegations, the Complaint asserts two causes of action on behalf of the Company: (1) violations of Section 14(a) of the Exchange Act against all defendants other than Cherevka; and (2) breach of fiduciary duty against all defendants. Based on these claims, the Complaint seeks judgment in favor of the Company and against the individual defendants in an unspecified amount of compensatory and restitution damages, together with pre- and post-judgment interest and costs of the action including reasonable attorneys’ and experts’ fees as well as a mandatory injunction requiring Ampio and the defendants to reform and improve the corporate governance and internal controls of the Company. On November 2, 2022, the Company and plaintiff (together with plaintiff in the previously filed Maresca On January 10, 2023, the Court granted consolidation of the Maresca Marquis co-lead counsel. On January 12, 2023, the Court granted the renewed motion and appointed co-lead counsel for plaintiffs. On January 17, 2023, the parties filed a joint stipulated motion seeking a temporary stay of the consolidated derivative actions, subject to various conditions, until the earlier of: (1) the dismissal of the Kain Kain As reported above, on January 4, 2024, the parties to the Consolidated Derivative Actions participated in a mediation at which they reached agreement in principle. The settlement is subject to various conditions, including the negotiation and execution of the full settlement agreements and obtaining court approval. On January 9, 2024, the parties filed a status report in the Consolidated Derivative Actions, advising the Court of the status of the settlement in principle and that the parties intended to file settlement documents within thirty days. Since then, the parties have filed several further status reports updating the Court on the parties’ continued negotiations and efforts to finalize the settlement documents. McCann v. Martino, et al On January 27, 2023, putative shareholder John McCann filed a derivative complaint in the District Court, City & County of Denver, State of Colorado, captioned McCann v. Martino et al Defendant Cherevka was served and by order dated February 9, 2023, obtained an extension of time to respond to the Complaint through March 31, 2023. On March 2, 2023, the parties filed a joint stipulated motion seeking a temporary stay of the action, subject to various conditions, until the earlier of: (1) the dismissal of the Kain Kain As reported above, on January 4, 2024, the parties to the McCann derivative action participated in the mediation at which the parties to the Consolidated Derivative Actions reached agreement in principle. The settlement of the Consolidated Derivative Action is subject to various conditions, including the negotiation and execution of the full settlement agreements and obtaining court approval. The plaintiffs in the McCann action have indicated their assent to the settlement of the Consolidated Derivative Actions and would seek dismissal of the McCann action if and when the Court finally approves the settlement of the Consolidated Derivative Actions. In accordance with ASC 450, Contingencies relieving the Company of any liability. It is reasonably possible that the estimated amount of the loss will change in the near term as the formal settlement(s) are finalized and approved by the court(s); however, the Company expects that payment would continue to be paid directly by the insurance carrier to the parties involved in the Shareholder Class Action and Consolidated Derivative Actions. SEC Investigation On October 12, 2022, the Securities and Exchange Commission, or SEC, entered an order directing private investigation and designating officers to take testimony to determine whether we or any other entities or persons have engaged in, or are about to engage in, any violations of the securities laws. The SEC has since issued subpoenas to the Company and numerous current and former officers, directors, employees and consultants of the Company. We intend to cooperate fully with the SEC.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2023
Employee Benefit Plan
Employee Benefit Plan	Note 14 – Employee Benefit Plan The Company has a 401(k) plan that allows participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. The Company provided $5,000 and $67,000 matching employee contributions during the year ended December 31, 2023 and December 31, 2022, respectively.

Subsequent Event

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2023
Subsequent Event
Subsequent Event	Note 15 – Subsequent Event ATM Agreement As of February 25, 2024, the Company received gross proceeds of $0.7 million from the sale of 301,928 shares of common stock from the ATM Agreement, which was offset by offering related costs of $99,000. In January 2024, the Company filed a prospectus supplement (the “Prospectus Supplement”) to the base prospectus included in the Registration Statement on Form S-3, which became effective under the Securities Act of 1933, as amended, on September 27, 2023, in connection with the ATM Agreement. Pursuant to the Prospectus Supplement, from time to time, the Company may offer and sell shares of its common stock having an aggregate gross sales price of up to $1,315,900. On February 26, 2024, the Company terminated the ATM Agreement with the Manager effective as of March 6, 2024. On February 28, 2024, the Company filed a post-effective amendment to deregister the remaining securities available under the Registration Statement relating to the offerings under the ATM Agreement, which was declared effective by the SEC on March 4, 2024. Litigation Update On January 11, 2024, the Company announced that a settlement in principle had been reached in the pending securities fraud class action, Case Number 22-cv-2105-WJM-MEH (the “Securities Class Action”), and the pending consolidated derivative actions in the United States District Court for the District of Colorado, Case Number 22-cv-2803-KLM (the “Consolidated Derivative Actions”). The settlements are subject to various conditions, including confirmatory discovery in the Securities Class Action, negotiation and execution of the full settlement agreements and obtaining court approval in each action. On January 9, 2024, Ampio along with the other parties to each case filed status reports in both the Securities Class Action and the Consolidated Derivative Actions, advising the respective courts of the status of the settlements in principle. The settlement of the Consolidated Derivative Actions is supported by the plaintiff in the pending Colorado state court derivative action, Case Number 2023CV30287, as well as stockholders who previously submitted pre-litigation demand letters to the Company’s Board of Directors. Ampio currently expects the amount to be paid in both settlements, including related defense costs, will be covered by, and within the limits of, its D&O insurance policy. The settlements in principle do not constitute any admission of fault, wrongdoing or liability as to the Company or any other defendant. While the timing of completion of the settlement agreements and filing motions to seek court approvals are uncertain, the Company will be endeavoring to finalize and execute the settlement agreements and have motions for preliminary approval submitted to the relevant courts by May 2024. If finally approved by the relevant courts, the settlements will result in the dismissal with prejudice of all of the pending civil actions and the withdrawal of the stockholder pre-litigation demands.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2023
Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions primarily include the Company’s projected current and long-term liquidity needs and availability and the insurance recovery receivable. The Company develops these estimates using its judgment based upon experience and the facts and circumstances known at the time.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s investment policy is to preserve principal and maintain liquidity. On March 10, 2023, the Federal Deposit Insurance Corporation (“FDIC”) placed Silicon Valley Bank (“SVB”) into receivership. At that time, the Company held approximately in a deposit account at SVB. The balance of the Company’s cash was held in an investment account that was not a deposit account and therefore, these amounts were not impacted by the FDIC’s receivership of SVB or subject to FDIC insurance limits. Following the joint statement by the U.S. Treasury, Federal Reserve and the FDIC on March 12, 2023, the Company regained access to all of its deposit account funds. The Company refined its cash management strategy in order to further mitigate the potential risk of loss associated with deposit accounts balances in excess of the FDIC insured amount.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the year ended December 31, 2023, the Company did not maintain balances in excess of the federally insured limits; however, during the year ended December 31, 2022, the Company maintained balances in excess of federally insured limits.
Insurance Recovery Receivable	During the second quarter of 2023, the Company’s legal expenses associated with the litigation proceedings exceeded the retention limit per the insurance policy and, as such, legal expenses incurred subsequently are covered and reimbursed by the insurance carrier. As of December 31, 2023, the Company estimated an insurance recovery receivable of
Fixed Assets	Fixed Assets Effective March 1, 2023, the Company entered into a sublease of its existing facility and in connection with that sublease, entered into a bill of sale with the subtenant for all the Company’s existing fixed assets (see Note 4
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company performs an evaluation on an annual basis, or sooner if management believes a triggering event has occurred, of the recoverability related to the carrying value of its long-lived assets to determine if facts and circumstances indicate that the carrying value of assets may be impaired and if any adjustment is warranted. As noted above, there were no long-lived or ROU assets to evaluate as of December 31, 2023. However, the Company recorded impairment charges of $1.6 million and $0.3 million on its long-lived and ROU assets, respectively, during the year ended December 31, 2022.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. The carrying amounts of cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short maturity of these instruments. In prior years, the Company recorded a warrant derivative liability associated with former offerings at estimated fair value based on utilization of the Black-Scholes warrant pricing model depending on facts and circumstances. However, the Company early adopted ASU 2020-06, resulting in the reclassification of the warrant derivative liability to stockholders’ equity, effective January 1, 2023. See Note 7 and Note 8
Share-Based Compensation	Share-Based Compensation The Company accounts for share-based payments by recognizing compensation expense based upon the estimated fair value of the share-based payments on the date of grant. The Company determines the estimated fair value of the share-based payments granted using the fair market value or Black-Scholes option pricing model and recognizes compensation costs ratably over the requisite service period which approximates the vesting period using the graded method. See Note 10
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its net deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through projected future taxable income, based primarily on the Company’s ongoing history of operating losses and the lack of taxable income in the foreseeable future. See Note 11
Research and Development	Research and Development Research and development costs are expensed as incurred in the respective periods.
Liquidity	Liquidity The Company is a pre-revenue stage biopharmaceutical company that has incurred an accumulated deficit of $242.5 million as of December 31, 2023. As of December 31, 2023, the Company had $4.1 million of cash and cash equivalents and an insurance recovery receivable of $0.9 million. As of February 29, 2024, the Company had $3.4 million in cash and cash equivalents and $0.5 million of an insurance recovery receivable. While the Company continued to implement cost reductions in 2023 and additional cost reductions in February and March 2024, the Company has finite cash resources available to fund its now limited operations. Its activities currently consist of taking steps to preserve cash to adequately fund an orderly wind down of the Company’s operations and to maximize the Company’s cash position and pursuit of the resolution of currently pending legal proceedings. Consistent with this goal, on March 25, 2024, the Board of Directors determined to pursue voluntary delisting of Ampio’s common stock from the NYSE American. After delisting, the Company expects to suspend its reporting obligations under the Exchange Act and deregister its common stock under Section 12(b) of the Exchange Act. Based on the above, these conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities; however, such adjustments may be necessary in the future when the Company is unable to continue as a going concern.
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements In August 2020, the Financial Accounting Standard Board (the “FASB”) issued ASU 2020-06, “ Debt (Subtopic 470-20); Debt with Conversion and Other Options and Derivatives and Hedging (Subtopic 815-40) Contracts in Entity’s Own Equity Recent Accounting Pronouncements This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	12 Months Ended
Prepaid Expenses and Other (Tables)	Dec. 31, 2023
Prepaid Expenses and Other
Schedule of Prepaid Expenses and other balances	December 31, 2023 December 31, 2022 Unamortized commercial insurance premiums $ 339,000 $ 610,000 Non-clinical trials (upfront payments) 215,000 — Deferred issuance costs 136,000 — Deposits 34,000 34,000 Other 3,000 32,000 Total prepaid expenses and other $ 727,000 $ 676,000

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
Fixed Assets (Tables)	Dec. 31, 2023
Fixed Assets
Schedule of Fixed Assets	Estimated Useful Lives (in Years) December 31, 2023 December 31, 2022 Leasehold improvements 10 $ — $ 4,965,000 Manufacturing facility/clean room 3 - 8 — 2,803,000 Lab equipment and office furniture 5 - 8 — 1,661,000 Fixed assets, gross — 9,429,000 Accumulated depreciation — (9,245,000) Fixed assets, net $ — $ 184,000
Schedule Of Depreciation expense	Year Ended December 31, 2023 2022 Depreciation and amortization expense $ 122,000 $ 1,048,000

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
Accounts Payable and Accrued Expenses (Tables)	Dec. 31, 2023
Accounts Payable and Accrued Expenses
Schedule of accounts payable and accrued expenses	December 31, 2023 December 31, 2022 Accounts payable $ 750,000 $ 97,000 Professional fees 706,000 157,000 Manufacturing development 274,000 — Commercial insurance premium financing 177,000 189,000 Non-clinical and clinical trials 73,000 89,000 Subtenant security deposit 62,000 — Franchise taxes 22,000 78,000 Property taxes — 74,000 Accrued severance — 143,000 Other 38,000 25,000 Accounts payable and accrued expenses $ 2,102,000 $ 852,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2023
Commitments and Contingencies
Summary of reconciliation of the Company's undiscounted payments for its facility lease and the carrying amount of the lease liability	Facility Lease Payments 2024 2025 2026 2027 2028 Thereafter Remaining Facility Lease Payments $ 280,000 $ 280,000 $ $ — $ — $ — $ — Less: Discount Adjustment (6,000) Total lease liability $ 274,000 Lease liability-current portion $ 274,000 Long-term lease liability $ —
Schedule of lease expense	Year Ended December 31, 2023 2022 Lease expense $ 113,000 $ 221,000

Warrants (Tables)

Warrants (Tables)	12 Months Ended
Warrants (Tables)	Dec. 31, 2023
Warrants.
Summary of Company's warrant activity	Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding as of December 31, 2022 53,263 $ 318.80 3.80 Forfeited, expired and/or cancelled (17,179) Outstanding as of December 31, 2023 36,084 $ 316.28 2.77
Schedule of stockholders equity note warrants or rights classified as equity and liability	Weighted Weighted Average Number of Average Remaining Date Exercise Price Type Warrants Exercise Price Contractual Life December 2021 registered direct offering $ 330.00 Investor 33,334 2.73 June 2019 public offering $ 150.00 Placement agent 2,750 0.04 Outstanding as of December 31, 2023 36,084 $ 316.28 2.77

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	12 Months Ended
Fair Value Considerations (Tables)	Dec. 31, 2023
Fair Value Considerations
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2023 and 2022, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total December 31, 2023 Liabilities: Warrant derivative liability $ — $ — $ — $ — December 31, 2022 Liabilities: Warrant derivative liability $ — $ — $ 44,000 $ 44,000

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
Common Stock (Tables)	Dec. 31, 2023
Common Stock.
Schedule of remaining authorized Shares	December 31, 2023 Authorized shares 300,000,000 Common stock outstanding 833,430 Options outstanding 12,291 Warrants outstanding 36,084 Reserved for issuance under 2019 Stock and Incentive Plan — Reserved for issuance under 2023 Stock and Incentive Plan 1,200,000 Available shares for future issuance 297,918,195

Mezzanine Equity and Stockhol_2

Mezzanine Equity and Stockholders' Equity (Tables)	12 Months Ended
Mezzanine Equity and Stockholders' Equity (Tables)	Dec. 31, 2023
Mezzanine Equity and Stockholders' Equity
Schedule of stock option activity	Weighted Weighted Average Number of Average Remaining Aggregate Options Exercise Price Contractual Life Intrinsic Value Outstanding as of December 31, 2022 14,873 $ 299.40 6.41 $ — Granted — Exercised — Forfeited, expired and/or cancelled (2,582) $ 352.49 Outstanding as of December 31, 2023 12,291 $ 288.12 6.81 $ — Exercisable as of December 31, 2023 11,652 $ 288.14 6.74 $ — Outstanding Options by Plan December 31, 2023 2010 Plan 4,508 2019 Plan 7,783 Outstanding as of December 31, 2023 12,291
Schedule of Stock Options Outstanding and Exercisable	Number of Weighted Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Lives Up to $150.00 2,040 $ 132.37 6.80 $150.01 - $300.00 5,935 $ 206.45 6.30 $300.01 - $450.00 2,620 $ 346.95 7.86 $450.01 and above 1,696 $ 670.16 6.98 Total 12,291 $ 288.12 6.81
Schedule of restricted stock awards activity	Weighted Average Grant-Date Aggregate Awards Fair Value Intrinsic Value Nonvested as of December 31, 2022 670 $ 492.00 Vested (223) $ 492.00 $ — Forfeited — Nonvested as of December 31, 2023 447 $ 492.00
Schedule of Assumptions Used in Computing Fair Value of All Options Granted	Year Ended December 31, 2022 Expected volatility 116.83% - 119.43 % Risk free interest rate 1.26% - 1.94 % Expected term (years) 5.45 - 6.51
Schedule of Stock-Based Compensation Expense	Year Ended December 31, 2023 2022 Research and development expenses Share-based compensation, net of forfeitures $ (25,000) $ 139,000 General and administrative expenses Share-based compensation, net of forfeitures 184,000 814,000 Total share-based compensation, net of forfeitures $ 159,000 $ 953,000 Unrecognized share-based compensation expense related to stock options as of December 31, 2023 $ 28,000 Weighted average remaining years to vest for stock options 1.00 Unrecognized share-based compensation expense related to restricted stock awards as of December 31, 2023 $ 34,000 Weighted average remaining years to vest for restricted stock awards 1.01

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2023
Income Taxes
Schedule of Effective Income Tax Rate Reconciliation	Year Ended December 31, 2023 2022 Benefit at federal statutory rate (21.0) % (21.0) % State, net of federal income tax impact (3.4) % (4.0) % Stock-based compensation 0.8 % 4.0 % Registered offering loss (gain)/warrant expense 0.0 % (7.2) % Change in state deferred tax rate 0.0 % 1.5 % Expiration of tax attribute carryforwards 0.3 % 0.6 % Other 0.0 % 0.0 % Change in valuation allowance 23.3 % 26.1 % Effective tax rate 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities	Year Ended December 31, 2023 2022 Long-term deferred income tax assets (liabilities): Accrued liabilities $ — $ 3,000 ROU asset — (18,000) Lease liability 67,000 150,000 Net operating loss carryforward 51,902,000 50,196,000 Share-based compensation 424,000 459,000 Unrealized loss on trading security 768,000 768,000 Property and equipment — 606,000 Warrants 65,000 65,000 Capitalized development costs 3,177,000 2,093,000 Asset retirement obligation — 68,000 Other 1,000 1,000 Less: Valuation allowance (56,404,000) (54,391,000) Total long-term deferred income tax assets (liabilities) $ — $ —

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
Earnings Per Share (Tables)	Dec. 31, 2023
Earnings Per Share
Schedule for the calculations of basic and diluted earnings per share	Year Ended December 31, 2023 2022 Net loss $ (8,632,000) $ (16,337,000) Less: decrease in fair value of investor warrants — (5,761,000) Net loss available to common stockholders $ (8,632,000) $ (22,098,000) Basic weighted-average common shares outstanding 810,113 753,615 Add: dilutive effect of equity instruments — — Diluted weighted-average shares outstanding 810,113 753,615 Earnings per share – basic $ (10.66) $ (21.68) Earnings per share – diluted $ (10.66) $ (29.32)
Schedule of potentially dilutive securities, excluded	Year Ended December 31, 2023 2022 Warrants to purchase shares of common stock 36,084 53,257 Outstanding stock options 12,291 14,873 Restricted stock awards 447 670 Total potentially dilutive shares of common stock 48,822 68,800

Basis of Presentation (Detail)

Basis of Presentation (Detail)	Dec. 31, 2023 USD ($)	Sep. 12, 2023	Sep. 11, 2023	Nov. 09, 2022	Dec. 31, 2022 USD ($)
Basis of Presentation
Stock split ratio	20	20	20	15
Cash and cash equivalents	$ 4,089,000				$ 12,653,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Detail) - USD ($)	Feb. 29, 2024	Dec. 31, 2023	Mar. 10, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies
Amount held in deposit account at SVB		$ 4,089,000		$ 12,653,000
Subsequent Event
Summary of Significant Accounting Policies
Amount held in deposit account at SVB	$ 3,400,000
SVB (Held as receivership by FDIC)
Summary of Significant Accounting Policies
Amount held in deposit account at SVB			$ 1,250,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Insurance Recovery Receivable (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies
Insurance recovery receivable	$ 920,000	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Fixed Assets and Impairment of Long-Lived Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies
Fixed assets, net	$ 0	$ 184,000
Right-of-use asset, net	0	75,000
Long-lived assets impairment	0	1,614,000
Right-of-use asset impairment	$ 0	$ 322,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Liquidity and Going Concern (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Feb. 29, 2024	Dec. 31, 2022
Summary of Significant Accounting Policies
Accumulated deficit	$ 242,527,000		$ 233,939,000
Cash and cash equivalents	4,089,000		12,653,000
Insurance recovery receivable	920,000		$ 0
Common stock issued, net of offering costs	$ 98,000
Subsequent Event
Summary of Significant Accounting Policies
Cash and cash equivalents		$ 3,400,000
Insurance recovery receivable		$ 500,000

Prepaid Expenses and Other - Pr

Prepaid Expenses and Other - Prepaid expenses and other balances (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expenses and Other
Unamortized commercial insurance premiums	$ 339,000	$ 610,000
Nonclinical trials (upfront payments)	215,000
Deferred issuance costs	136,000
Deposits	34,000	34,000
Other	3,000	32,000
Total prepaid expenses and other	$ 727,000	$ 676,000

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	3 Months Ended
Fixed Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		10 years
Fixed assets, gross			$ 9,429,000
Accumulated depreciation			(9,245,000)
Fixed assets, net		$ 0	184,000
Impairment loss	$ 1,600,000
Leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		10 years
Fixed assets, gross			4,965,000
Manufacturing facility/clean room
Property, Plant and Equipment [Line Items]
Fixed assets, gross			2,803,000
Manufacturing facility/clean room \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		3 years
Manufacturing facility/clean room \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		8 years
Lab equipment and office furniture
Property, Plant and Equipment [Line Items]
Fixed assets, gross			$ 1,661,000
Lab equipment and office furniture \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		5 years
Lab equipment and office furniture \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		8 years

Fixed Assets - Depreciation Exp

Fixed Assets - Depreciation Expenses (Details) - USD ($)	12 Months Ended
Fixed Assets - Depreciation Expenses (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Fixed Assets
Depreciation and amortization expense	$ 122,000	$ 1,048,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Accounts Payable and Accrued Expenses
Accounts payable	$ 750,000	$ 97,000
Professional fees	706,000	157,000
Manufacturing development	274,000
Commercial insurance premium financing	177,000	189,000
Nonclinical and clinical trials	73,000	89,000
Subtenant security deposit	62,000
Franchise taxes	22,000	78,000
Property taxes		74,000
Accrued severance		143,000
Other	38,000	25,000
Accounts payable and accrued expenses	$ 2,102,000	$ 852,000

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses - Commercial Insurance Premium Financing Agreement (Details) - Commercial Insurance Premium Financing Agreement - USD ($)	1 Months Ended
	Jun. 30, 2023	Dec. 31, 2023
Debt Instrument [Line Items]
Financing agreement amount	$ 700,000
Term of agreement (in years)	9 months
Interest rate (as a percentage)	8%
Insurance down payment	$ 171,000
Principal and interest payments per month	$ 59,000
Outstanding obligation amount		$ 177,000

Commitments and Contingencies -

Commitments and Contingencies - Employment Agreements (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Mr. Daniel Stokely
Related Party Transaction [Line Items]
Annual Salary	$ 335,000
Mr. Michael A. Martino
Related Party Transaction [Line Items]
Annual Salary	$ 550,000

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Details)			1 Months Ended
	Mar. 01, 2023 USD ($)	Dec. 13, 2013 USD ($)	Dec. 31, 2023 USD ($) item	Mar. 15, 2024 USD ($)	Sep. 30, 2023 USD ($)
Commitments and Contingencies [Line Items]
Manufacturing development			$ 274,000
Gain on elimination of ARO obligation	$ 294,000
Non Cash gain on derecognition of ARO	289,000
Loss on derecognition of ARO asset	$ 5,000
Manufacturing Development Agreement
Commitments and Contingencies [Line Items]
Contractual obligation					$ 1,600,000
Cost of change orders			20,000
Manufacturing Development Agreement \| Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Accrued and unpaid services and related expenses				$ 160,000
Non-Clinical Trials
Commitments and Contingencies [Line Items]
Contractual obligation					$ 105,000
Cost of change orders			$ 117,000
Number of additional non-clinical agreements \| item			4
Additional contractual commitment			$ 625,000
Non-Clinical Trials \| Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Accrued and unpaid services and related expenses				$ 32,000
Newly Leased Office Space and Manufacturing Facility
Commitments and Contingencies [Line Items]
Non-cancellable operating lease period		125 months
Lease renewal term		60 months
Lease initial base rent per month		$ 23,000
Rent expense		$ 3,300,000

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Reconciliation of Company's Undiscounted Payments for Facility Lease and Carrying Amount of Lease Liability (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2024	$ 280,000
Remaining Facility Lease Payments	280,000
Less: Discount Adjustment	(6,000)
Total lease liability	274,000
Lease liability - current portion	274,000	$ 340,000
Long-term lease liability	$ 0	$ 274,000

Commitments and Contingencies_4

Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies
Lease expense	$ 113	$ 221

Warrants - Warrants Activity (D

Warrants - Warrants Activity (Details) - $ / shares	12 Months Ended
Warrants - Warrants Activity (Details) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Number of Warrants Outstanding
Warrants outstanding	36,084	53,263
Number of Warrants Outstanding, Beginning Balance	53,263
Number of Warrants, Forfeited, expired and/or cancelled	(17,179)
Number of Warrants Outstanding, Ending Balance	36,084	53,263
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 318.80
Weighted Average Exercise Price, Outstanding Ending Balance	$ 316.28	$ 318.80
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	2 years 9 months 7 days	3 years 9 months 18 days
Equity based-warrants
Number of Warrants Outstanding
Warrants outstanding	36,100
Number of Warrants Outstanding, Ending Balance	36,100

Warrants - Warrants Activity Cl

Warrants - Warrants Activity Classified as Equity and Liability (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding	36,084	53,263
Exercise price	$ 316.28	$ 318.80
Weighted Average Remaining Contractual Life, Warrants Outstanding	2 years 9 months 7 days	3 years 9 months 18 days
Investor Warrants, December 2021 Registered Direct Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding	33,334
Exercise price	$ 330
Weighted Average Remaining Contractual Life, Warrants Outstanding	2 years 8 months 23 days
Placement Agent, June 2019 Public offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding	2,750
Exercise price	$ 150
Weighted Average Remaining Contractual Life, Warrants Outstanding	14 days

Warrants - Narrative (Detail)

Warrants - Narrative (Detail) - USD ($)	12 Months Ended
Warrants - Narrative (Detail) - USD ($)	Dec. 31, 2023	Aug. 31, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Number of warrants issued or exercised	0
Warrant derivative liability	$ 0		$ 44,000
Investor Warrants
Class of Warrant or Right [Line Items]
Warrants expired		512
2021 Warrants
Class of Warrant or Right [Line Items]
Number of warrants abandoned	16,667
Warrant abandonment, consideration	$ 0

Fair Value Considerations - Fin

Fair Value Considerations - Financial Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
LIABILITIES
Warrant derivative liability	$ 0		$ 44,000
Fair Value, Inputs, Level 3
LIABILITIES
Warrant derivative liability	$ 0		$ 44,000
Fair Value, Inputs, Level 3 \| ASU 2020-06 \| Cumulative Effect, Period of Adoption, Adjustment
LIABILITIES
Warrant derivative liability		$ 44,000

Common Stock - Summarizes the C

Common Stock - Summarizes the Company's remaining authorized shares available (Details) - shares	Dec. 31, 2023	Dec. 31, 2022
Components Of Common Stock [Line Items]
Authorized shares	300,000,000	300,000,000
Common stock outstanding	833,430	804,674
Options outstanding	12,291	14,873
Warrants outstanding	36,084	53,263
Available shares for future issuance	297,918,195
2019 Stock plan
Components Of Common Stock [Line Items]
Options outstanding	7,783
2023 Stock plan
Components Of Common Stock [Line Items]
Reserved for issuance Stock and Incentive Plan	1,200,000

Common Stock - ATM Equity Offer

Common Stock - ATM Equity Offering Program (Details) - USD ($)			12 Months Ended
	Sep. 27, 2023	Sep. 18, 2023	Dec. 31, 2023	May 24, 2023	Dec. 31, 2022
Common Stock
Common Stock, par value		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Aggregate sales price		$ 1,250,000
Proceeds from Issuance of Common Stock	$ 1,315,900
Manager
Common Stock
Additional reimbursement of expenses paid		$ 2,500
ATM Agreement
Common Stock
Number of common stock shares issued			28,826
Proceeds from Issuance of Common Stock			$ 100,000
Placement agent commissions and issuance costs			$ 100,000
ATM Agreement \| Manager
Common Stock
Percentage of commission		3%
Maximum reimbursement of out of pocket expenses paid to third parties		$ 50,000
Number of days within which prior notice is given on termination of agreement		7 days

Mezzanine Equity and Stockhol_3

Mezzanine Equity and Stockholders' Equity - Preferred Stock (Details) - $ / shares			12 Months Ended
	Jul. 27, 2023	Jun. 08, 2023	Dec. 31, 2023	Sep. 18, 2023	May 24, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, par value			$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Issuance of Series D preferred stock dividend			0
Series D Preferred
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred Stock, Par value					$ 0.0001
Issuance of Series D preferred stock dividend		15,103
Redemption price per ten shares	$ 0.01
Number of shares considered for calculating redemption price	10

Mezzanine Equity and Stockhol_4

Mezzanine Equity and Stockholders' Equity - Activity of Plan (Details) shares in Millions	Dec. 31, 2023	Sep. 12, 2023	Sep. 11, 2023	Nov. 09, 2022	Jul. 31, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock split ratio	20	20	20	15
2019 Stock plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for equity awards					1.2

Mezzanine Equity and Stockhol_5

Mezzanine Equity and Stockholders' Equity - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of Options
Number of Options, Beginning Balance	14,873
Number of Options, Forfeited, expired and/or cancelled	(2,582)
Number of Options, Ending Balance	12,291	14,873
Number of Options, Exercisable	11,652
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance	$ 299.40
Weighted Average Exercise Price, Forfeited, expired and/or cancelled	352.49
Weighted Average Exercise Price, Ending Balance	288.12	$ 299.40
Weighted Average Exercise Price, Exercisable	$ 288.14
Weighted Average Remaining Contractual Life, Outstanding	6 years 9 months 21 days	6 years 4 months 28 days
Weighted Average Remaining Contractual Life, Exercisable	6 years 8 months 26 days
2010 Stock Plan
Number of Options
Number of Options, Ending Balance	4,508
2019 Stock plan
Number of Options
Number of Options, Ending Balance	7,783

Mezzanine Equity and Stockhol_6

Mezzanine Equity and Stockholders' Equity - Summary of Stock Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding \| shares	12,291
Weighted Average Exercise Price	$ 288.12
Weighted Average Remaining Contractual Lives	6 years 9 months 21 days
Up to $150.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding \| shares	2,040
Weighted Average Exercise Price	$ 132.37
Weighted Average Remaining Contractual Lives	6 years 9 months 18 days
Range of Exercise Prices Lower	$ 450.01
Range of Exercise Prices Upper	$ 150
$150.01 - $300.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding \| shares	5,935
Weighted Average Exercise Price	$ 206.45
Weighted Average Remaining Contractual Lives	6 years 3 months 18 days
Range of Exercise Prices Lower	$ 150.01
Range of Exercise Prices Upper	$ 300
$300.01 - $450.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding \| shares	2,620
Weighted Average Exercise Price	$ 346.95
Weighted Average Remaining Contractual Lives	7 years 10 months 9 days
Range of Exercise Prices Lower	$ 300.01
Range of Exercise Prices Upper	$ 450
$450.01 and above
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding \| shares	1,696
Weighted Average Exercise Price	$ 670.16
Weighted Average Remaining Contractual Lives	6 years 11 months 23 days

Mezzanine Equity and Stockhol_7

Mezzanine Equity and Stockholders' Equity - Restricted Stock Awards (Details) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Awards
Nonvested as of beginning \| shares	670
Vested (Shares) \| shares	(223)
Nonvested as of ending \| shares	447
Average Grant-Date Fair Value
Nonvested at beginning (Dollars per share) \| $ / shares	$ 492
Vested (Dollars per share) \| $ / shares	492
Nonvested at ending (Dollars per share) \| $ / shares	$ 492

Mezzanine Equity and Stockhol_8

Mezzanine Equity and Stockholders' Equity - Assumptions Used in Computing Fair Value of All Options Granted (Details) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, Minimum	116.83%
Expected volatility, Maximum	119.43%
Risk free interest rate, Minimum	1.26%
Risk free interest rate, Maximum	1.94%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 5 months 12 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 6 months 3 days

Mezzanine Equity and Stockhol_9

Mezzanine Equity and Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation, net of forfeitures	$ 159,000	$ 953,000
Unrecognized share-based compensation expense related to stock options as of September 30, 2023	28,000
Unrecognized share-based compensation expense related to restricted stock awards as of September 30, 2023	$ 34,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining years to vest	1 year
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation, net of forfeitures	$ 83,000	500,000
Reversals for non-vested shares for director and employee forfeitures		500,000
Weighted average remaining years to vest	1 year 3 days
Research and development expenses \| Share-based compensation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation, net of forfeitures	$ (25,000)	139,000
General and administrative expenses \| Share-based compensation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation, net of forfeitures	$ 184,000	$ 814,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Taxes
Benefit at federal statutory rate	(21.00%)	(21.00%)
State, net of federal income tax impact	(3.40%)	(4.00%)
Stock-based compensation	0.80%	4%
Registered offering gain / warrant expense	0%	(7.20%)
Change in state deferred tax rate	0%	1.50%
Expiration of tax attribute carryforwards	0.30%	0.60%
Other	0%	0%
Change in valuation allowance	23.30%	26.10%
Effective tax rate	0%	0%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Long-term deferred income tax assets (liabilities):
Accrued liabilities		$ 3,000
ROU Asset		(18,000)
Lease liability	$ 67,000	150,000
Net operating loss carryforward	51,902,000	50,196,000
Share-based compensation	424,000	459,000
Unrealized loss on trading security	768,000	768,000
Property and equipment		606,000
Warrants	65,000	65,000
Capitalized development costs	3,177,000	2,093,000
Asset retirement obligation		68,000
Other	1,000	1,000
Less: Valuation allowance	(56,404,000)	(54,391,000)
Total long-term deferred income tax assets (liabilities)	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 212
Operating Loss Carryforward, Carries Forward Indefinitely	$ 81.5
Minimum
Income Taxes [Line Items]
Percentage Of Likelihood Of Tax Benefit Being Realized	50%

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($)		12 Months Ended
Earnings Per Share (Details) - USD ($)		Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share
Net loss		$ (8,632,000)	$ (16,337,000)
Less: decrease in fair value of investor warrants			(5,761,000)
Net loss available to common stockholders		$ (8,632,000)	$ (22,098,000)
Basic weighted-average common shares outstanding	[1]	810,113	753,615
Diluted weighted-average shares outstanding	[1]	810,113	753,615
Earnings per share - basic	[1]	$ (10.66)	$ (21.68)
Earnings per share - diluted	[1]	$ (10.66)	$ (29.32)

[1]Net loss per common share and weighted average number of common shares outstanding for the current period have been adjusted and the prior periods have been retroactively adjusted to reflect the 20-to-1 reverse stock split effected September 12, 2023.

Earnings Per Share - Anti-dilut

Earnings Per Share - Anti-dilutive (Details) - shares	12 Months Ended
Earnings Per Share - Anti-dilutive (Details) - shares	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	48,822	68,800
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	36,084	53,257
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	12,291	14,873
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	447	670

Litigation (Details)

Litigation (Details) $ in Millions	Nov. 17, 2023	Oct. 16, 2023 D	Sep. 20, 2023	Nov. 07, 2022 item	Nov. 02, 2022 item	Oct. 17, 2022 item	Oct. 07, 2022 item	Aug. 17, 2022 item	Dec. 31, 2023 USD ($)
Kain v. Ampio Pharmaceuticals, Inc., et al., 22-cv-2105
Loss Contingencies [Line Items]
Number of former executives against whom a securities fraud class action has been filed								2
Number of putative shareholders who filed motions seeking to be named lead plaintiff						6
Number of movants filed oppositions to each other's motions				2
Defendants term to file notice for amended complaint		60 days
Litigation case, number of business days \| D		5
Term to file a substitute			90 days
Term to file status report by parties	5 days
Maresca v. Martino, et al., 22-cv-2646-KLM
Loss Contingencies [Line Items]
Number of defendants who are in violation of the Company's insider trading restrictions							2
Number of causes of action as asserted by the Complaint							6
Marquis v. Martino, et al., 22-cv-2803-KLM
Loss Contingencies [Line Items]
Number of derivative actions to be consolidated					2
Number of plaintiffs appointed as co-lead counsel					2
McCann v. Martino, et al., 2023cv30287 \| Securities Class Action [Member]
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss \| $									$ 3
McCann v. Martino, et al., 2023cv30287 \| Consolidated Derivative Actions [Member]
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss \| $									$ 0.5

Employee Benefit Plan (Detail)

Employee Benefit Plan (Detail) - USD ($)	12 Months Ended
Employee Benefit Plan (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Employee Benefit Plan
Matching employee contributions provided by the company	$ 5,000	$ 67,000

Subsequent Events (Details)

Subsequent Events (Details)				12 Months Ended
Subsequent Events (Details)	Feb. 15, 2024 USD ($) shares	Jan. 11, 2024 stockholder	Sep. 27, 2023 USD ($)	Dec. 31, 2023 USD ($) shares
Subsequent Events
Proceeds from issuance of common stock			$ 1,315,900
ATM Agreement
Subsequent Events
Proceeds from issuance of common stock				$ 100,000
Number of common stock shares issued \| shares				28,826
Offering related cost				$ 100,000
Subsequent Event \| Case Number 22-cv-2105-WJM-MEH and Case Number 22-cv-2803-KLM \| Settled Litigation
Subsequent Events
Number of stockholders submitted pre litigation demand letters \| stockholder		2
Number of stockholders submitted pre litigation demand letters \| stockholder		2
Subsequent Event \| ATM Agreement
Subsequent Events
Proceeds from issuance of common stock	$ 700,000
Number of common stock shares issued \| shares	301,928
Offering related cost	$ 99,000

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
Pay vs Performance Disclosure - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (8,632,000)	$ (16,337,000)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false